Artigo Completo - Open Access.

Idioma principal | Segundo idioma

Technical Change and the Incorporation of Biotechnology in the Pharmaceutical Industry

Technical Change and the Incorporation of Biotechnology in the Pharmaceutical Industry

MATOS, Murilo Montanari de; QUEIROZ, Sérgio Robles Reis de;

Artigo Completo:

A indústria farmacêutica, ao longo de sua história, tem enfrentado inúmeras mudanças e desafios. Atualmente o setor passa por uma crise de produtividade em suas atividades de P&D. Este fato coloca uma série de questionamentos importantes, para o escopo deste estudo destacam-se dois: Como a indústria tem lidado com esta crise? As atitudes do setor trazem novas mudanças ou dinâmicas a este mesmo? A resposta que este artigo propõe é também o argumento que se procura defender, que é: a solução tentada pela indústria farmacêutica é tanto tecnológica quanto organizacional e esta solução reside fora das fronteiras da firma, sendo assim, as grandes empresas farmacêuticas estão usando estratégias, especialmente as aquisições de pequenas empresas de biotecnologia, para incorporar novas tecnologias que, em tese, vão aumentar a taxa inovativa das grandes empresas. Para se conseguir o objetivo proposto, este trabalho propõe combinar uma pesquisa bibliográfica focada na literatura econômica e na literatura especializada nas técnicas usadas para se desenvolver novas drogas para que se observe a evolução das atividades de P&D. Ademais, alguns dados importantes serão apresentados para sustentar algumas afirmações. Como conclusão, o artigo mostra que a evolução das atividades de P&D criou uma necessidade, nas grandes empresas farmacêuticas, que fez a incorporação de pequenas empresas de biotecnologia uma estratégia recorrente.

Artigo Completo:

The pharmaceutical industry has undergone several changes and challenges, nowadays the industry is facing a R&D productivity crises. A series of questions arise from this fact, two of it can be highlighted as important for this study that are: how the industry is dealing with this crises? Does it bring new features to the sector? The answer that this article proposes it is also our argument, that is: the solution sought by the industry is both technological and organizational and it resides outside the large pharmaceutical enterprise’s borders, therefore, those companies are using strategies, especially acquisitions of small biotech enterprises to incorporate new technologies that, arguably, will increase the large enterprise’s innovative output. Therefore this article objective is to prove the argument. In order to achieve the objective proposed this work proposes to combine bibliographic research on the economic literature and the specialized literature on drug discovery techniques to describe this activity evolution, in addition, some important data will be present to sustain the assertions made. As a conclusion the article shows that the R&D activities evolution has created a biotechnology trajectory, in the pharmaceutical companies, that made the incorporation of small biotech enterprises a recurrent strategy.

Palavras-chave: biotecnologia, indústria farmacêutica, mudança técnica, competências, aquisições,

Palavras-chave: biotechnology, pharmaceutical industry, technical change, competences, acquisitions,

DOI: 10.5151/enei2017-06

Referências bibliográficas
  • [1] ACHILLADELIS, B.; ANTONAKIS, N. The dynamics of technological innovation: the case of the pharmaceutical industry. In: Research Policy, n. 30, pp 535-588, 2001
  • [2] ADRETSCH, D. The Role of Small Firms in U.S. Biotechnological Clusters. In: Small Business Economics, 17, pp. 3-15, 2001.
  • [3] AHUJA, G. AND KATILA, R. Technological acquisitions and the innovation performance of acquiring firms: a longitudinal study. In: Strategic Management Journal, 22, pg. 197-220, 2001
  • [4] AMZEL, M. Structure-based drug design. In: Current opinion in biotechnology,9(4), 366-369, 1998.
  • [5] ANDERSSEN, M., XIAO, J. Acquisitions of start-ups by incumbent businesses a market selection process of “high-quality” entrants? In: Research Policy, 45, pg. 272-290, 2016.
  • [6] CAMPOS, A. A reiew of the influence of long-term patterns in research and technological development (R&D) formalization on university-industry links. In: RevistaBrasileira de Inovação, Vol. 9, n.2, 2010
  • [7] COMANOR, W.; SCHERER, M.. “Mergers and Innovation in the Pharmaceutical Industry.” Journal of Health Economics 32 (1), 2013
  • [8] CASSIMAN, B.; VEUGELERS, R. In Search of Complementarity in Innovation Strategy: Internal R&D and External Knowledge Acquisition. In: Management Science, vol. 52, n. 1, pp. 68-82, 2006
  • [9] CHAKRABARTI, A., HAUSCHILDT, J., SUVERKRUP, C. Does it pay to acquire technological firms? In: R&D Management, 24, pg. 47-56, 1994
  • [10] COHEN, W. M., LEVINTHAL, D. A. Innovation and learning: the two faces of R&D. Economic Journal, 99, 397, 569-596, 1989.
  • [11] COMANOR, W.; SCHERER, F. Mergers and Innovation in the pharmaceutical industry. In: Journal of Health Economics, 32, pp 106-113, 2013.
  • [12] GANE, P.; DEAN, P. Recent advances in structure-based rational drug design. In: Current Opinion in Structural Biology, 10:401–404, 2000.
  • [13] DiMASI, J. New drug innovation and pharmaceutical industry structure: trends in the output of pharmaceutical firms. In: Drug information Journal, Vol. 34. pp. 1169-1194, 2000.
  • [14] DiMASI, J.; GRABOWSKI, H. The cost of biopharmaceuticals R&D: is biotech different? In: Managerial and Decision Economics, 28, pp. 469-470, 2007.
  • [15] DREWS, J. Drug Discovery: A Historical Perspective. In: Science, vol 287, 2000
  • [16] GAMBARDELLA, A. Science and Innovation: The U.S. Pharmaceutical industry During the 1980’s, Cambridge University Press, Cambridge, 1995.
  • [17] GASSMAN, O.; REEPMEYER, G.; VON ZEDTWITZ, M. Leading Pharmaceutical Innovation: Trends and Drivers for growth in the Pharmaceutical Industry, Springer-Verlag, Berlin, 2005
  • [18] GISLING, V.; NOTEBOON, B. Exploration and explotation in Innovation systems: The case of pharmaceuticals biotechnology. In: Research Policy, n. 35, pp 1-23, 2006.
  • [19] GLEADLE, P.; PARRIS, S.; SHIPMAN, A.; SIMONETT, R. Restructuring and Innovation in pharmaceutical and biotechs: The impacts of financialisation. In: Critical Perspect Account, 2013
  • [20] GRABOWSKI, H. G.; VERNON, J., M. Consumer protection regulation in ethical drugs, American Economic Review 67(2), 359-364, 1977.
  • [21] GRABOWSKI, H.; VERNON, J. The pharmaceutical Industry. In: NELSON, R. (ed) Government and technical Progress: A Cross-Industry Analysis, Pergamon Press, New York, 1982.
  • [22] GRABOWSKI, H.; VERNON, J. Returns to R&D on new drug introductions in the 1980s. In: Journal of Health Economics 13, pg. 383-406, 1994
  • [23] GRABOWSKI, H.; VERNON, J. The determinants of pharmaceutical research and development expenditures. In: Journal of Evolutionary Economics, 10, pp 201-215, 2000.
  • [24] HAGEDOORN, J.; DUYSTERS, G. The effect of Mergers and Acquisitions on the Technological Performance of Companies in a High-tech Environment. In: technology Analysis & Strategic Management, 14:1, pp 67-85, 2002.
  • [25] HIGGINS, M.; RODRIGUEZ, D. The outsourcing of R&D through acquisitions in the pharmaceutical industry. In: Journal of Financial Economics, n. 80, pp351-383, 2006.
  • [26] HOPKINS, M.; MARTIN, P.; NIGHTINGALE, P.; KRAFT, A.; MADHI, S.; The myth of the biotech revolution: An assessment of technological, clinical and organizational change. In: Research Policy, 36, pp 566-589, 2007
  • [27] HOPKINS, M.; NIGHTINGALE, P.; BADEN-FULLER, C. “Servant Firms in Drug Discovery: A Neglected Project Based Organizational Form.” SSRN Working Paper Series, 1–36, 2012
  • [28] HOUSTON, J., G.; BANKS, M. The Chemical-biological interface: developments in automated and miniaturized screening technology. In: Current Opinion in Biotechnology, 8, pp 734-740, 1997
  • [29] HUSSINGER, K. On the importance of technological relatedness: SMEs versus Large acquisitions targets. In: Technovation, 30, pg. 57-64, 2010
  • [30] KENNEY, M. Biotechnology: The University-Industrial Complex, Yale University Press, New Haven, 1987
  • [31] MACARRON, R.; BANKS, M. N.; BOJANIC, D.; BURNS, D. J.; CIROVIC, D. A.; GARYANTES, T.; CHOPFER, U. Impact of high-throughput screening in biomedical research. In: Nature reviews Drug discovery, 10(3), 188-195, 2011.
  • [32] MALERBA, F., ORSENIGO, L. The evolution of the pharmaceutical industry. In: Business History, 57:5, 664-687, 2015
  • [33] MAKRI, M.; HITT, A.; LANE, P. Complementary Technologies, Knowledge Relatedness and Invention Outcomes in High Technology Mergers and Acquisitions. In: Strategic Management Journal, 31, pp. 602-628, 2010.
  • [34] MATOS, M., M. “Changes in Innovation Dynamics of the Pharmaceutical Industry: A Study of the Interaction between Large pharmaceutical Companies and the Acquired Small Biotechnology Enterprises”. Tese de doutorado, Unicamp, Agosto, 2016.
  • [35] MARTIN, P.; Genes as drugs: the social shaping of gene therapy and the reconstruction of genetic disease. In: Sociology of Health & Illness, v. 21, n.5, 1999
  • [36] MARTIN, P., HOPKINS, M., NIGHTINGALE, P., KRAFT, A. On a critical path: genomics, the crisis of pharmaceutical productivity and the search for sustainability. In: In: ATKINSON, P., GLASNER, P., LOCK, M., (eds)Handbook of Genetics & Society: Mapping the New Genomic Era, pp 145-161, 2011
  • [37] MORGAN, S., GROOTENDORST, P., LEXCHIN, J., CUNNINGHAM, C., GREYSON, D. The cost of drug development: A systematic review. In: Health Policy, 100, pg. 4-17, 2011.
  • [38] MOWERY, D., ROSENBERG, N. Trajetórias da Inovação: Mudança tecnológica nos Estados Unidos da America no século XX. EditoraUnicamp, Campinas, 2006
  • [39] MUNOS, B. Lessons form 60 years of pharmaceutical innovation. In: Nature Reviews Drug Discovery, 8, pp. 959-968, 2009.
  • [40] NIGHTINGALE, P. Economics of scale in pharmaceutical experimentation. In: industrial and Corporate change, n. 9, pp. 315-359, 2000.
  • [41] NIGHTINGALE, P.; MADHI, S. The evolution of pharmaceutical innovation. In: MAZZUCATO, M.; DOSI, G. (eds) Knowledge Accumulation and Industry Evolution, Cambridge University Press, Cambridge, 2006.
  • [42] PAMMOLLI, F.; MAGAZZINI, L.; RICCABONI, M. The productivity crisis in the pharmaceutical R&D. In: Nature Reviews Drug Discovery, 10, pp. 428-438.
  • [43] PAUL, S.; MYTELKA, D.; DUNWIDDIE, C.; PERSINGER, C.; MUNOS, B.; LINBORG, S.; SCHACHT, A. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. In: Nature Reviews Drug Discover, vol. 9, 2010.
  • [44] PEREIRA, D. A.; WILLIAMS, J. A. Origin and evolution of high throughput screening. In:British journal of pharmacology,152(1), 53-61, 2007.
  • [45] POWELL, W.; KOPUT, K.; SMITH-DOERR, L.; Interorganizacional collaboration and the locus of innovation networks of learning in biotechnology. In: Administrative Science Quarterly, 41, pp. 116-145, 1996
  • [46] QUÉRÉ, M. The post-genome era: rupture in the organization of the life science industry? In: McKELVEY, M., RICKNE, A., LAAGE-HELLMAN, J. The Economic Dynamics of Modern Biotechnology, Edward Elgar, Northhampton, USA, 2004
  • [47] SHARP, M. The Science of Nations; European Multinationals and American Biotechnology, Biotechnology, 1(1):132-162, 1996
  • [48] SZÜCS, F. M&A and R&D: asymmetric effects on acquirers and targets? IN: Research Policy, 43, pg. 1264-1273, 2014.
  • [49] SCHIMID, E.; JAMES, K.; SMITH, D. The Impact of Technological Advances on Drug Discovery Today. In: Drug Information Journal, vol. 35, pp. 41-45, 2001.
  • [50] SCHWARDT, O.; KOLB, H.; ERNST, B. Drug Discovery Today. In: Current Topics in Medicinal Chemistry, 3, 1-9, 2003
  • [51] SCHWARTZMAN, D. Innovation in the Pharmaceutical Industry, The Johns Hopkins university Press, Baltimore, Maryland, 1976
  • [52] SCHWEIZER, L. Organizational interaction of Acquired Biotechnology Companies into Pharmaceutical Companies: The need for a Hybrid Approach. In: Academy of Management Journal, vol. 48, n. 6, pp. 1051-1074, 2005.
  • [53] TEECE, D. Profiting from technological innovation: Implications for integrations, collaboration, licensing and public policy. In: Research Policy, v.15, n.6, pp 285-305, 1986
  • [54] U.S. Congress, Office of Technology Assessment, Biotechnology in a Global Economy,OTA-BA-494 (Washington, DC: U.S. Government Printing Office, October 1991).
  • [55] ZUCKER, L.; DARBY, M. Present the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm. In: Research Policy, 26, pp. 429-446, 1997.
Como citar:

MATOS, Murilo Montanari de; QUEIROZ, Sérgio Robles Reis de; "Technical Change and the Incorporation of Biotechnology in the Pharmaceutical Industry", p. 92-109 . In: . São Paulo: Blucher, 2017.
ISSN 2357-7592, DOI 10.5151/enei2017-06

últimos 30 dias | último ano | desde a publicação


downloads


visualizações


indexações